EP
APTO

Equius Partners’s Aptose Biosciences, Inc. APTO Stock Holding History

Equius Partners’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$14.5K Hold
56
– – ﹤0.01% 28
2022
Q3 		$15K Hold
56
– – 0.01% 18
2022
Q2 		$19K Hold
56
– – 0.01% 16
2022
Q1 		$34K Hold
56
– – 0.01% 16
2021
Q4 		$34K Buy
+56
New +$52.6K 0.01% 18

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
AC
Annandale Capital Dallas, Texas $709M AUM 11.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Equius Partners's APTO Position: Q4 2022 in Review

Equius Partners held its Aptose Biosciences, Inc. (APTO) position steady in Q4 2022 at 56 shares worth $14.5K. The position accounts for ﹤0.01% of the portfolio, ranked #28.

Equius Partners first reported a position in APTO in Q4 2021 and has held it in 5 quarters since. The position peaked at $34K in Q1 2022. 47 funds tracked by Wall St. Rank hold APTO as of Q4 2022.

  • Equius Partners held 56 shares of Aptose Biosciences, Inc. worth $14.5K as of Q4 2022.
  • Equius Partners left its Aptose Biosciences, Inc. share count unchanged in Q4 2022.
  • Aptose Biosciences, Inc. made up ﹤0.01% of Equius Partners's portfolio in Q4 2022, its #28 holding.
  • Equius Partners first reported a position in Aptose Biosciences, Inc. in Q4 2021 and has held it in 5 quarters since.
  • Equius Partners's Aptose Biosciences, Inc. position peaked at $34K in Q1 2022.
  • 47 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q4 2022.

Based on Equius Partners's 13F filing for Q4 2022, filed 27 Jan 2023.